FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890554254> ?p ?o ?g. }

• W2890554254 abstract "e20677 Background: Amrubicin (AMR) is a totally synthetic 9-aminoanthracycline and clinically active against non-small cell lung cancer (NSCLC). We found that the combination of AMR and erlotinib (ERL) had significant synergistic effect on NSCLC cell line with wild-type EGFR in vitro. We conducted a phase I study of AMR and ERL combination therapy in previously treated patients with advanced NSCLC, and have already reported the safety and the effectiveness. Furthermore we observed a high response rate of 33% in EGFR wild-type NSCLC. Methods: We conducted a multi-center, single-arm phase II trial to evaluate the efficacy of AMR and ERL combination therapy in patients with previously treated, advanced NSCLC, PS 0-1, and aged < 75 years, EGFR wild type. Patients were treated at 3weeks intervals with AMR(35mg/m 2 , intravenous injection on days 1-3) plus ERL(100mg/day, once daily on days 1-21). The primary endpoint is progression free survival (PFS). Secondary endpoints are response rate (RR), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and toxicity. The concentration of trough ERL was measured after first cycle of treatment as additional investigation. Results: From June 2013 to July 2016, 25 patients were enrolled in this trial. The PFS according to the central test was 3.6 months (95%CI 2.1 - 5.1). The RR and the DCR were 24.0% and 64.0%, respectively. We observed grade 3 or 4 hematological toxicities such as leukopenia (68%), neutropenia (72%), anemia (8%) and febrile neutropenia (12%). The grade 3 or 4 non-hematological toxicities were anorexia (12%), oral mucositis (12%) and rash (8%). We had no treatment related death in this study. Conclusions: The PFS of AMR and ERL combination therapy in this study was superior to that of AMR monotherapy in historical setting. This combination therapy might be an option for previously treated NSCLC patients without a driver oncogene mutation. Clinical trial information: UMIN 000010582. Clinical trial information: UMIN 000010582." @default.
• W2890554254 created "2018-09-27" @default.
• W2890554254 creator A5004024254 @default.
• W2890554254 creator A5004383942 @default.
• W2890554254 creator A5017282699 @default.
• W2890554254 creator A5021722390 @default.
• W2890554254 creator A5024626188 @default.
• W2890554254 creator A5045329864 @default.
• W2890554254 creator A5045658682 @default.
• W2890554254 creator A5045893818 @default.
• W2890554254 creator A5047998541 @default.
• W2890554254 creator A5056477482 @default.
• W2890554254 creator A5068149602 @default.
• W2890554254 creator A5073485705 @default.
• W2890554254 creator A5083502759 @default.
• W2890554254 creator A5089223839 @default.
• W2890554254 date "2017-05-20" @default.
• W2890554254 modified "2023-09-27" @default.
• W2890554254 title "Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type EGFR (TORG1320)." @default.
• W2890554254 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20677" @default.
• W2890554254 hasPublicationYear "2017" @default.
• W2890554254 type Work @default.
• W2890554254 sameAs 2890554254 @default.
• W2890554254 citedByCount "0" @default.
• W2890554254 crossrefType "journal-article" @default.
• W2890554254 hasAuthorship W2890554254A5004024254 @default.
• W2890554254 hasAuthorship W2890554254A5004383942 @default.
• W2890554254 hasAuthorship W2890554254A5017282699 @default.
• W2890554254 hasAuthorship W2890554254A5021722390 @default.
• W2890554254 hasAuthorship W2890554254A5024626188 @default.
• W2890554254 hasAuthorship W2890554254A5045329864 @default.
• W2890554254 hasAuthorship W2890554254A5045658682 @default.
• W2890554254 hasAuthorship W2890554254A5045893818 @default.
• W2890554254 hasAuthorship W2890554254A5047998541 @default.
• W2890554254 hasAuthorship W2890554254A5056477482 @default.
• W2890554254 hasAuthorship W2890554254A5068149602 @default.
• W2890554254 hasAuthorship W2890554254A5073485705 @default.
• W2890554254 hasAuthorship W2890554254A5083502759 @default.
• W2890554254 hasAuthorship W2890554254A5089223839 @default.
• W2890554254 hasConcept C121608353 @default.
• W2890554254 hasConcept C126322002 @default.
• W2890554254 hasConcept C143998085 @default.
• W2890554254 hasConcept C2776256026 @default.
• W2890554254 hasConcept C2776694085 @default.
• W2890554254 hasConcept C2778087573 @default.
• W2890554254 hasConcept C2779438470 @default.
• W2890554254 hasConcept C31760486 @default.
• W2890554254 hasConcept C502942594 @default.
• W2890554254 hasConcept C71924100 @default.
• W2890554254 hasConceptScore W2890554254C121608353 @default.
• W2890554254 hasConceptScore W2890554254C126322002 @default.
• W2890554254 hasConceptScore W2890554254C143998085 @default.
• W2890554254 hasConceptScore W2890554254C2776256026 @default.
• W2890554254 hasConceptScore W2890554254C2776694085 @default.
• W2890554254 hasConceptScore W2890554254C2778087573 @default.
• W2890554254 hasConceptScore W2890554254C2779438470 @default.
• W2890554254 hasConceptScore W2890554254C31760486 @default.
• W2890554254 hasConceptScore W2890554254C502942594 @default.
• W2890554254 hasConceptScore W2890554254C71924100 @default.
• W2890554254 hasLocation W28905542541 @default.
• W2890554254 hasOpenAccess W2890554254 @default.
• W2890554254 hasPrimaryLocation W28905542541 @default.
• W2890554254 isParatext "false" @default.
• W2890554254 isRetracted "false" @default.
• W2890554254 magId "2890554254" @default.
• W2890554254 workType "article" @default.